485 related articles for article (PubMed ID: 25682550)
1. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
Kane JM; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
Schizophr Res; 2015 May; 164(1-3):127-35. PubMed ID: 25682550
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.
Ishigooka J; Iwashita S; Tadori Y
Psychiatry Clin Neurosci; 2018 Sep; 72(9):692-700. PubMed ID: 29774628
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
Schizophr Res; 2016 Jul; 174(1-3):82-92. PubMed ID: 27157799
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
Fleischhacker WW; Hobart M; Ouyang J; Forbes A; Pfister S; McQuade RD; Carson WH; Sanchez R; Nyilas M; Weiller E
Int J Neuropsychopharmacol; 2017 Jan; 20(1):11-21. PubMed ID: 27566723
[TBL] [Abstract][Full Text] [Related]
7. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
Marder SR; Hakala MJ; Josiassen MK; Zhang P; Ouyang J; Weiller E; Weiss C; Hobart M
Acta Neuropsychiatr; 2017 Oct; 29(5):278-290. PubMed ID: 27846922
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
9. Brexpiprazole for the treatment of schizophrenia.
Yee A
Expert Rev Neurother; 2016; 16(2):109-22. PubMed ID: 26650624
[TBL] [Abstract][Full Text] [Related]
10. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.
Grossberg GT; Kohegyi E; Mergel V; Josiassen MK; Meulien D; Hobart M; Slomkowski M; Baker RA; McQuade RD; Cummings JL
Am J Geriatr Psychiatry; 2020 Apr; 28(4):383-400. PubMed ID: 31708380
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
13. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
Citrome L; Ota A; Nagamizu K; Perry P; Weiller E; Baker RA
Int Clin Psychopharmacol; 2016 Jul; 31(4):192-201. PubMed ID: 26963842
[TBL] [Abstract][Full Text] [Related]
14. Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
Citrome L; Ouyang J; Shi L; Meehan SR; Baker RA; Weiss C
J Clin Psychopharmacol; 2019; 39(6):597-603. PubMed ID: 31652166
[TBL] [Abstract][Full Text] [Related]
15. Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder.
Cantillon M; Prakash A; Alexander A; Ings R; Sweitzer D; Bhat L
Schizophr Res; 2017 Nov; 189():126-133. PubMed ID: 28215471
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
17. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
[TBL] [Abstract][Full Text] [Related]
18. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
McIntyre RS; Weiller E; Zhang P; Weiss C
J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
[TBL] [Abstract][Full Text] [Related]
19. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Antoun Reyad A; Girgis E; Mishriky R
Int Clin Psychopharmacol; 2020 May; 35(3):119-128. PubMed ID: 32141908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
